Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 3120.

https://doi.org/10.1182/blood-2019-124349

Published: 2019

Journal Articles

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Marco Basset, MD, Irene Defrancesco, MD, Paolo Milani, MD, Sara Rattotti, MD, Andrea Foli, MD, Marzia Varettoni, MD, Alessandro Corso, MD, Marco Paulli, Giampaolo Merlini, MD, Luca Arcaini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2018-99-118161

Published: 2018

Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Meletios A Dimopoulos, MD, Katja Weisel, MD, Philippe Moreau, Larry Anderson, MD PhD, Darrell J White, MD, Jesus F San-Miguel, MD PhD, Pieter Sonneveld, MD PhD, Monika Engelhardt, MD, Matthew W Jenner, Alessandro Corso, MD, Jan Dürig, Michel Pavic, MD, Morten Salomo, Xin Yu, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Mohamed Zaki, MD PhD, Paul Richardson

Blood (2018) 132 (Supplement 1): 3278.

https://doi.org/10.1182/blood-2018-99-111869

Published: 2018

Journal Articles

Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study

Vittorio Montefusco, MD, Alessandro Corso, MD, Monica Galli, MD PhD, Elena Tagliabue, Sara Pezzatti, Francesca Patriarca, MD, Filippo Gherlinzoni, MD, Renato Zambello, MD, Simona Sammassimo, Magda Marcatti, MD, Andrea Nozza, Claudia Crippa, MD, Anna Maria Cafro, MD, Luca Baldini, Paolo Corradini, MD

Blood (2017) 130 (Supplement 1): 836.

https://doi.org/10.1182/blood.V130.Suppl_1.836.836

Published: 2017

Journal Articles

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Giovanni Palladini, MDPhD, Marco Basset, MD, Paolo Milani, MD, Marzia Varettoni, MD, Silvia Mangiacavalli, MD, Francesca Russo, MD, Andrea Foli, MD, Alessandro Corso, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 1760.

https://doi.org/10.1182/blood.V130.Suppl_1.1760.1760

Published: 2017

Journal Articles

The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity

Laura Oliva, Ugo Orfanelli, Massimo Resnati, Andrea Raimondi, Andrea Orsi, Enrico Milan, Giovanni Palladini, Paolo Milani, Fulvia Cerruti, Paolo Cascio, Simona Casarini, Paola Rognoni, Thierry Touvier, Magda Marcatti, Fabio Ciceri, Silvia Mangiacavalli, Alessandro Corso, Giampaolo Merlini, Simone Cenci

Blood (2017) 129 (15): 2132–2142.

https://doi.org/10.1182/blood-2016-08-730978

Published: 2017

Includes: Supplemental data

Journal Articles

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Federica Cocito, MD, Silvia Mangiacavalli, MD, Virginia Valeria Ferretti, PhD, Claudio Salvatore Cartia, MD, Maya Ganzetti, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2016) 128 (22): 5711.

https://doi.org/10.1182/blood.V128.22.5711.5711

Published: 2016

Journal Articles

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Silvia Mangiacavalli, MD, Federica Cocito, MD, Virginia Valeria Ferretti, PhD, Claudio Salvatore Cartia, MD, Maya Ganzetti, MD, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2016) 128 (22): 5695.

https://doi.org/10.1182/blood.V128.22.5695.5695

Published: 2016

Journal Articles

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

Blood (2016) 128 (22): 4494.

https://doi.org/10.1182/blood.V128.22.4494.4494

Published: 2016

Journal Articles

Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Blood (2015) 126 (23): 3034.

https://doi.org/10.1182/blood.V126.23.3034.3034

Published: 2015

Journal Articles

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Blood (2014) 124 (21): 3458.

https://doi.org/10.1182/blood.V124.21.3458.3458

Published: 2014

Journal Articles

Confocal Microscopy Is Useful for Detection of Bortezomib Related Neuropathy (BOR-PN) in Multiple Myeloma (MM) Patients (PTS)

Federica Cocito, MD, Silvia Mangiacavalli, MD, Gabriella Ricciardelli, MD, Virginia Ferretti, PhD, Roberto Ceccuzzi, MD, Mario Cazzola, MD, paolo Emilio Bianchi, MD, Alessandro Corso

Blood (2014) 124 (21): 5691.

https://doi.org/10.1182/blood.V124.21.5691.5691

Published: 2014

Journal Articles

Treated Multiple Myeloma Patients: Demographic Characteristics, Incidence Rate and Mortality in Lombardy during the 2003-2009 Period

Paolo Corradini, MD, Alessandro Corso, MD, Lorenzo Giovanni Mantovani, Monica Galli, MD, Anna Maria Cafro, MD, Roberta Ciampichini, Paolo Cozzolino, Virginio Chiodini, Claudia Crippa, MD, Giuseppe Rossi, Giancarlo Cesana, Enrica Morra, MD

Blood (2014) 124 (21): 1329.

https://doi.org/10.1182/blood.V124.21.1329.1329

Published: 2014

Journal Articles

Direct Healthcare Costs of Treated Multiple Myeloma: Results from a Population-Based Study

Alessandro Corso, Enrica Morra, MD, Paolo Corradini, MD PhD, Monica Galli, MD, Anna Maria Cafro, MD, Roberta Ciampichini, Paolo Cozzolino, Virginio Chiodini, Claudia Crippa, MD, Giuseppe Rossi, Giancarlo Cesana, Lorenzo Giovanni Mantovani

Blood (2014) 124 (21): 1315.

https://doi.org/10.1182/blood.V124.21.1315.1315

Published: 2014

Journal Articles

High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents

Silvia Mangiacavalli, MD, Alessandra Pompa, MD, Cristiana Pascutto, PhD, Virginia Ferretti, DR, Lara Pochintesta, MD, Federica Cocito, MD, Marzia Varettoni, Mario Lazzarino, Prof, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2013) 122 (21): 1896.

https://doi.org/10.1182/blood.V122.21.1896.1896

Published: 2013

Journal Articles

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study

Samantha Pozzi, MD, Stefania Badiali, MS, Alessandro Corso, MD, Pellegrino Musto, MD, Attilio Guarini, MD, Carla Minoia, MD, Donatella Vincelli, MD, Roberto Ria, MD, Luciano Masini, MD, Giovanni Quarta, MD, Massimo Gentile, MD, Carla Mazzone, MD, Antonio Palumbo, MD, Fortunato Morabito, MD, Stefano Sacchi, MD

Blood (2013) 122 (21): 3212.

https://doi.org/10.1182/blood.V122.21.3212.3212

Published: 2013

Journal Articles

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms

Marzia Varettoni, Luca Arcaini, Silvia Zibellini, Emanuela Boveri, Sara Rattotti, Roberta Riboni, Alessandro Corso, Ester Orlandi, Maurizio Bonfichi, Manuel Gotti, Cristiana Pascutto, Silvia Mangiacavalli, Giorgio Croci, Valeria Fiaccadori, Lucia Morello, Maria Luisa Guerrera, Marco Paulli, Mario Cazzola

Blood (2013) 121 (13): 2522–2528.

https://doi.org/10.1182/blood-2012-09-457101

Published: 2013

Journal Articles

A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma

Stefano Sacchi, Samantha Pozzi, Stefania Badiali, Attilio Guarini, Carla Mazzone, Alessandro Corso, Donatella Vincelli, Luciano Masini, Pellegrino Musto, Roberto Ria, Giovanni Quarta, Antonio Lazzaro, Antonio Palumbo, Fortunato Morabito

Blood (2012) 120 (21): 1851.

https://doi.org/10.1182/blood.V120.21.1851.1851

Published: 2012

Journal Articles

Bone Marrow Aspirate Can Be Avoided in Low-Risk MGUS Patients

Silvia Mangiacavalli, Federica Cocito, MD, Lara Pochintesta, Cristiana Pascutto, Alessandra Pompa, Mario Cazzola, Alessandro Corso

Blood (2012) 120 (21): 3997.

https://doi.org/10.1182/blood.V120.21.3997.3997

Published: 2012

Journal Articles

Serum C-Terminal Telopeptide Maintains Its Correlation with Bone Disease in Myeloma Patients Even Under Treatment with Bisphosphonates

Lara Pochintesta, Silvia Mangiacavalli, MD, Federica Cocito, MD, Cristiana Pascutto, Alessandra Pompa, Mario Cazzola, Alessandro Corso

Blood (2012) 120 (21): 4003.

https://doi.org/10.1182/blood.V120.21.4003.4003

Published: 2012

NARROW

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Confocal Microscopy Is Useful for Detection of Bortezomib Related Neuropathy (BOR-PN) in Multiple Myeloma (MM) Patients (PTS)

Treated Multiple Myeloma Patients: Demographic Characteristics, Incidence Rate and Mortality in Lombardy during the 2003-2009 Period

Direct Healthcare Costs of Treated Multiple Myeloma: Results from a Population-Based Study

High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms

A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma

Bone Marrow Aspirate Can Be Avoided in Low-Risk MGUS Patients

Serum C-Terminal Telopeptide Maintains Its Correlation with Bone Disease in Myeloma Patients Even Under Treatment with Bisphosphonates

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only